CA2429898C - Dispositifs et procedes servant a lutter contre le cholesterol - Google Patents

Dispositifs et procedes servant a lutter contre le cholesterol Download PDF

Info

Publication number
CA2429898C
CA2429898C CA2429898A CA2429898A CA2429898C CA 2429898 C CA2429898 C CA 2429898C CA 2429898 A CA2429898 A CA 2429898A CA 2429898 A CA2429898 A CA 2429898A CA 2429898 C CA2429898 C CA 2429898C
Authority
CA
Canada
Prior art keywords
cholesterol
drug
dosage form
drug delivery
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2429898A
Other languages
English (en)
Other versions
CA2429898A1 (fr
Inventor
Harry A. J. Struijker-Boudier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Durect Corp
Original Assignee
Durect Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Durect Corp filed Critical Durect Corp
Publication of CA2429898A1 publication Critical patent/CA2429898A1/fr
Application granted granted Critical
Publication of CA2429898C publication Critical patent/CA2429898C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Formes galéniques à libération contrôlée sous forme d'implant, dispositifs et procédés servant à administrer un agent abaissant le cholestérol.
CA2429898A 2000-11-16 2001-11-08 Dispositifs et procedes servant a lutter contre le cholesterol Expired - Fee Related CA2429898C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24964400P 2000-11-16 2000-11-16
US60/249,644 2000-11-16
PCT/US2001/046714 WO2002067895A2 (fr) 2000-11-16 2001-11-08 Dispositifs et procedes servant a lutter contre le cholesterol

Publications (2)

Publication Number Publication Date
CA2429898A1 CA2429898A1 (fr) 2002-09-06
CA2429898C true CA2429898C (fr) 2011-02-22

Family

ID=22944385

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2429898A Expired - Fee Related CA2429898C (fr) 2000-11-16 2001-11-08 Dispositifs et procedes servant a lutter contre le cholesterol

Country Status (3)

Country Link
EP (1) EP1335704A2 (fr)
CA (1) CA2429898C (fr)
WO (1) WO2002067895A2 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
CA2508124A1 (fr) * 2002-12-19 2004-07-08 Alza Corporation Gels stables non aqueux a phase unique et formulations, destines a etre administres a partir d'un dispositif implantable
JP2006521897A (ja) 2003-03-31 2006-09-28 アルザ・コーポレーション 内部圧力を放散する手段を備える浸透ポンプ
KR20060002922A (ko) 2003-03-31 2006-01-09 알자 코포레이션 비수성 단일 상 비히클 및 이러한 비히클을 이용한 제형
WO2006083761A2 (fr) 2005-02-03 2006-08-10 Alza Corporation Solutions de solvant/polymere utilisees comme vehicules de suspension
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
ES2351527T3 (es) 2006-05-30 2011-02-07 Intarcia Therapeutics, Inc Modulador de flujo en dos piezas con conducto interno para un sistema osmótico de administración.
NZ574524A (en) 2006-08-09 2011-07-29 Intarcia Therapeutics Inc Piston assembly for positioning lumen of a reservoir for an osmotic delivery having a columnar body and a spring
EP2157967B1 (fr) 2007-04-23 2013-01-16 Intarcia Therapeutics, Inc Formulations en suspension de peptides insulinotropes et leurs utilisations
HUE030789T2 (en) * 2007-05-18 2017-06-28 Durect Corp Improved depot formulation
CN101801415B (zh) 2007-05-25 2015-09-23 Rb医药品有限公司 利培酮化合物的持续递送制剂
WO2009102467A2 (fr) 2008-02-13 2009-08-20 Intarcia Therapeutics, Inc. Dispositifs, formulations et méthodes d’administration de plusieurs agents bénéfiques
LT2462246T (lt) 2009-09-28 2017-11-27 Intarcia Therapeutics, Inc Esminio stacionaraus vaisto tiekimo greitas įgyvendinimas ir (arba) nutraukimas
SG191737A1 (en) * 2010-12-20 2013-08-30 Cormatrix Cardiovascular Inc A drug eluting patch for the treatment of localized tissue disease or defect
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US11154559B2 (en) 2011-09-29 2021-10-26 Ethicon Endo-Surgery, Inc. Methods and compositions of bile acids
US20140308352A1 (en) 2013-03-11 2014-10-16 Zogenix Inc. Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material
CN105163719B (zh) 2013-03-11 2019-03-08 度瑞公司 包含高粘度液体载体的可注射控制释放组合物
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
JP6993235B2 (ja) 2015-06-03 2022-01-13 インターシア セラピューティクス，インコーポレイティド インプラントの設置及び撤去システム
EP3458084B1 (fr) 2016-05-16 2020-04-01 Intarcia Therapeutics, Inc Polypeptides sélectifs pour le récepteur du glucagon et méthodes pour leur utilisation
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
KR20190104039A (ko) 2017-01-03 2019-09-05 인타르시아 세라퓨틱스 인코포레이티드 Glp-1 수용체 효능제의 연속적인 투여 및 약물의 동시-투여를 포함하는 방법
WO2021146215A1 (fr) 2020-01-13 2021-07-22 Durect Corporation Systèmes d'administration de médicament à libération prolongée avec impuretés réduites et procédés associés

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ239370A (en) * 1990-08-22 1994-04-27 Merck & Co Inc Bioerodible implantable controlled release dosage form comprising a poly(ortho ester) or a polyacetal with an active agent incorporated into the chain backbone
GB9105152D0 (en) * 1991-03-12 1991-04-24 Glaxo Group Ltd Chemical compounds
CA2336879C (fr) * 1998-07-20 2010-06-01 Peptech Limited Compositions a liberation prolongee contenant des peptides, des polypeptides, des proteines ou des acides nucleiques comme principes actifs

Also Published As

Publication number Publication date
CA2429898A1 (fr) 2002-09-06
WO2002067895A3 (fr) 2003-04-17
EP1335704A2 (fr) 2003-08-20
WO2002067895A2 (fr) 2002-09-06

Similar Documents

Publication Publication Date Title
CA2429898C (fr) Dispositifs et procedes servant a lutter contre le cholesterol
US20040142902A1 (en) Implant dosage form and use thereof for the delivery of a cholosterol lowering agent
US20040115236A1 (en) Devices and methods for management of inflammation
EP0290891B1 (fr) Système à libération retardée d'un médicament pour le traitement des troubles nerveux
Tiwari et al. Statins therapy: a review on conventional and novel formulation approaches
EP0948320B1 (fr) COMPOSITIONS PHARMACEUTIQUES POUR LA LIBERATION PROLONGEE DE FLUVASTATINE INHIBANT LA REDUCTASE DE HMG-CoA
CA2502146A1 (fr) Solutions de sirolimus et de ses analogues pour le traitement de la coronaropathie
US6797727B2 (en) Use of rhein or diacerhein compounds for the treatment or prevention of vascular diseases
Verma et al. Single intravenous dose of novel flurbiprofen-loaded proniosome formulations provides prolonged systemic exposure and anti-inflammatory effect
CN110035743B (zh) 一种Talazoparib药物组合物及其应用
US20020151876A1 (en) Devices and methods for management of bone density
KR20170056573A (ko) 치료제의 고도로 국소화된 방출을 위한 주입가능한 미립자
WO2018108164A1 (fr) Composition pharmaceutique de bortézomib et ses applications
Shen et al. Design of controlled release drug delivery systems
AU2002258361A1 (en) Implant dosage form and use thereof for the delivery of a cholesterol lowering agent
AU2007216719A1 (en) Implant dosage form and use thereof for the delivery of a cholesterol lowering agent
US20210401775A1 (en) A liquid injectable composition
AU2004316087A1 (en) Biocompatible polymeric delivery systems for sustained release of quinazolinones
AU2007202061B2 (en) Devices and methods for management of inflammation
Rastogi et al. Evaluation of a perforated drug delivery system in mice for prolonged and constant release of a hydrophilic drug
Singh et al. MODIFIED RELEASE DRUG DELIVERY SYSTEM: CONCEPT AND SYSTEM DESIGN OF RATE-CONTROLLED DRUG DELIVERY SYSTEM
AU2002250038A1 (en) Devices and methods for management of bone density
DiPiro Controlling drug effects through improved oral formulations: The pharmacokinetics of the prazosin gastrointestinal therapeutic system
Tiwari et al. AN OVERVIEW: SUSTAINED RELEASE DRUG DELIVERY TECHNOLOGIES WITH POLYMERIC SYSTEM.
Siepmann et al. Time-Controlled Drug Delivery Systems

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed
MKLA Lapsed

Effective date: 20121108